The first multiplex immunoassay systems have already been approved by the US Food and Drug Administration. This advance implies that miniaturized and parallelized array techniques for protein detection have finally been recognized as powerful tools for predictive early diagnosis of disease. Committed to the development of disease diagnostics strategies over years, Creative Biolabs has established our technology platform and we are confident in offering high-quality protein array development for disease diagnostics services.
Protein-detecting microarrays employ a wide variety of capture agents (antibodies, fusion proteins, DNA RNA aptamers, synthetic peptides, carbohydrates, and small molecules) immobilized at high spatial density on a solid surface to selectively extract target proteins from complex mixtures, including serum and cell lysate samples. Extracted proteins may then be rapidly detected and quantified. This approach enables large-scale analyses of protein interactions across the entire proteome (comprehensive proteome analysis) as well as experiments focusing on a limited number of protein interactions (focused proteome analysis) in a high-throughput fashion with less consumption of the sample than occurs with other methods. The protein-detecting microarray is no longer a vision, but rather an indispensable tool for comprehensive proteomic studies that is especially applicable to prediction/early diagnosis of disease.
Fig.1 Representative capture agents of protein-detecting microarrays. (Tomizaki, 2010)
The elucidation of blood protein markers that allow more accurate or earlier diagnosis of prostate cancer should have a positive impact on prostate cancer treatment and management. In this context, serum samples from control subjects and patients with benign or malignant prostatic disease were analyzed with antibody arrays targeting multiple candidate prostate cancer markers. Several potential disease-associated protein alterations were discovered, and significant elevation of thrombospondin-1 was observed in patients with benign prostatic cancer disease, with repression in patients with prostate cancer being the most significant.
Specific antimicrobial antibodies present in the sera of patients with IBD are valuable serological biomarkers for the diagnosis prognosis of IBD. The whole E. coli proteome microarray analysis identified 169 proteins as highly immunogenic in healthy controls, 186 proteins as highly immunogenic in Crohn's disease (CD) patients, and only 19 proteins as highly immunogenic in ulcerative colitis (UC) patients. Novel biomarkers for specifically distinguishing CD patients from healthy controls (accuracy: 86.4%) and CD from UC patients (accuracy: 80.2%) were found using a supervised learning algorithm.
An independent study using synovial proteome microarrays containing 225 peptides and proteins that represented candidate and control antigens identified that distinct serum antibody profiles in patients with RA. Autoreactive B-cell responses were identified that targeted citrullinated epitopes in distinct subsets of patients who had early RA with a significant predictive predisposition to severe RA. These studies suggested the potential of proteomic analysis for both diagnosis and severity based sub-classification of patients with RA, primarily based on their cytokine and autoantibody profiles.
Fig.2 Flow-chart depiction of the various formats and detection strategies available for protein array technologies with applications in autoimmunity. (Szodoray, 2011)
Focusing on the in vitro diagnostics (IVD) development services for years, Creative Biolabs has equipped advanced technologies, the latest facilities, professional expertise, and excellent scientific staff. With all the progress we made step-by-step in practice, we are capable of providing high-quality protein array development services to global customers.
As a global-leading biotechnology company, Creative Biolabs has never stopped making progress. Every effort we made is to provide better service to our customers. If you are interested in protein array development for disease diagnostics services or any other IVD development services, please don't hesitate to contact us for more information.
References
For Research Use Only.
